FibroGen Inc Cash Flow-to-Debt Ratio
FibroGen Inc cash flow-to-debt ratio. FibroGen Inc (FGEN) has a Cash Flow-to-Debt Ratio of -0.02x as of September 2025, meaning its operating cash flow of $-1.85 Million could theoretically repay 0% of its total liabilities ($119.53 Million) in one year. Check earnings quality score of FibroGen Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of FibroGen Inc (2012–2024)
Cash flow-to-debt ratio of FibroGen Inc from 2012 to 2024. Historical debt coverage capacity for FibroGen Inc across 13 annual periods. Check how aggressively does FibroGen Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
FibroGen Inc Cash Flow-to-Debt Ratio by Year (2012–2024)
FibroGen Inc cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for FibroGen Inc. For the full cash flow conversion analysis, see how efficiently does FibroGen Inc generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.35x | $-138.00 Million | $398.16 Million | ▲ +35.6% |
| 2023 | -0.54x | $-315.02 Million | $585.73 Million | ▼ -125.4% |
| 2022 | -0.24x | $-145.93 Million | $611.57 Million | ▼ -58.1% |
| 2021 | -0.15x | $-82.23 Million | $544.71 Million | ▼ -171.3% |
| 2020 | 0.21x | $81.60 Million | $385.39 Million | ▲ +186.6% |
| 2019 | -0.24x | $-78.70 Million | $321.99 Million | ▼ -13.0% |
| 2018 | -0.22x | $-76.14 Million | $352.13 Million | ▼ -2.8% |
| 2017 | -0.21x | $-66.51 Million | $316.20 Million | ▼ -971.4% |
| 2016 | 0.02x | $7.11 Million | $294.44 Million | ▲ +135.6% |
| 2015 | -0.07x | $-18.57 Million | $273.75 Million | ▼ -173.5% |
| 2014 | 0.09x | $22.41 Million | $242.85 Million | ▼ -32.6% |
| 2013 | 0.14x | $25.92 Million | $189.35 Million | ▲ +450.2% |
| 2012 | -0.04x | $-5.61 Million | $143.40 Million | — |